MBRX – moleculin biotech, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

MBRX

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

12/15

02:03 am

mbrx

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Low Report

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Report

12/11

08:08 am

mbrx

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model [Yahoo! Finance]

Low Report

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model [Yahoo! Finance]

Report

12/11

08:00 am

mbrx

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

Low Report

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

Report

12/7

02:07 am

mbrx

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Low Report

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Report

11/29

03:10 am

mbrx

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Medium Report

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Report

11/21

03:09 am

mbrx

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Medium Report

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Report

11/18

08:15 am

mbrx

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Medium Report

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Report

11/14

08:18 am

mbrx

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 [Yahoo! Finance]

High Report

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 [Yahoo! Finance]

Report

11/14

08:15 am

mbrx

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

High Report

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Report

11/13

03:02 am

mbrx

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Medium Report

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Report

11/13

02:07 am

mbrx

Moleculin Biotech Reports Financial Highlights and Future Plans [Yahoo! Finance]

Medium Report

Moleculin Biotech Reports Financial Highlights and Future Plans [Yahoo! Finance]

Report

11/12

02:31 pm

mbrx

Moleculin Biotech, Inc. (NASDAQ: MBRX) had its price target lowered by analysts at Maxim Group from $20.00 to $8.00. They now have a "buy" rating on the stock.

Low Report

Moleculin Biotech, Inc. (NASDAQ: MBRX) had its price target lowered by analysts at Maxim Group from $20.00 to $8.00. They now have a "buy" rating on the stock.

Report

11/12

08:00 am

mbrx

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Medium Report

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Report

11/11

07:47 am

mbrx

Moleculin Biotech GAAP EPS of -$2.85 [Seeking Alpha]

High Report

Moleculin Biotech GAAP EPS of -$2.85 [Seeking Alpha]

Report

11/11

07:09 am

mbrx

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]

Low Report

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]

Report

11/11

07:05 am

mbrx

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

High Report

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Report

11/5

09:00 am

mbrx

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Medium Report

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Report

11/5

02:15 am

mbrx

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Low Report

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Report

11/4

08:30 am

mbrx

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Low Report

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Report

10/28

02:03 am

mbrx

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Low Report

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Report

10/20

02:08 am

mbrx

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Low Report

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Report

10/17

08:51 am

mbrx

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available [Yahoo! Finance]

Low Report

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available [Yahoo! Finance]

Report

10/17

08:40 am

mbrx

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Medium Report

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Report

10/12

02:05 am

mbrx

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Medium Report

Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Report

10/7

08:30 am

mbrx

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

Medium Report

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.